Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Depressive Disorders: Etiology

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Psychosocial characteristics and cognitive function in community-dwelling adults over 50 years old from the Mexican Health and Aging Study (MHAS).

Psicologia, conocimiento y sociedad·2026

Same author

A Mediation Analysis of Oral Health, Anthropometric Characteristics and Frailty Among Community-Dwelling Mexican Older Adults.

Gerodontology·2026

Same author

Structural factors of disability and ageing: spatial patterns in Mexico.

BMC public health·2026

Same author

Association of cognitive reserve with 9-year domain-specific cognitive trajectories and risk of cognitive impairment in Mexican older adults.

PloS one·2025

Same author

Normative Data for the Montreal Cognitive Assessment (MoCA) in Mexican Adults: A Regression-Based Approach.

Diagnostics (Basel, Switzerland)·2025

Same author

Citizens' Jury as a Strategy to Increase Social Participation Among Older People.

Health expectations : an international journal of public participation in health care and health policy·2025

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Depressive symptoms and APOE polymorphisms in an elderly population-based sample.

Carmen García-Peña¹, Teresa Juarez-Cedillo, David Cruz-Robles

¹Epidemiologic and Health Service Research Unit, Aging Area, Instituto Mexicano del Seguro Social.

Psychiatric Genetics

|May 1, 2010

Summary

Apolipoprotein E (APOE) gene variations are not a direct risk factor for depression in older adults. However, the APOE*4 allele may be linked to cognitive difficulties, suggesting a role in some depressive symptoms.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Related Experiment Videos

Last Updated: Jun 13, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Area of Science:

Genetics
Neuroscience
Gerontology

Background:

Apolipoprotein E (APOE) is a key gene associated with Alzheimer's disease risk.
Previous research suggests a potential link between APOE and depression in elderly individuals.

Purpose of the Study:

To investigate the association between APOE gene polymorphisms and depression in elderly adults.

Main Methods:

A Mexican population-based sample of individuals over 60 years old (n=1566) was genotyped for APOE polymorphisms using TaqMan assays.

Main Results:

No significant association was found between APOE alleles/genotypes and depression or anxiety.
Individuals with the APOE*4 allele showed more impairment in thinking and concentration compared to those with the APOE*3 allele.

Conclusions:

Genetic variations in the APOE gene may influence specific depressive symptoms in late-onset depression.
APOE is not identified as a specific risk factor for depression itself, but may affect cognitive aspects of depressive symptoms.